|
Characteristics
|
No. of Patients (%)
|
No. of Deaths (%)*
|
P
†
|
MST (95% CI, month)
|
P
‡
|
|---|
|
Age
| | |
0.456
| |
0.468
|
|
≤ 60 years
|
55 (44.4)
|
39 (70.9)
| |
21.0 (13.0-32.0)
| |
|
> 60 years
|
69 (56.6)
|
53 (76.8)
| |
18.0 (13.0-26.0)
| |
|
Gender
| | |
0.175
| |
0.046
|
|
Female
|
57 (46.0)
|
39 (68.4)
| |
26.0 (17.0-38.0)
| |
|
Male
|
67 (54.0)
|
53 (79.1)
| |
17.0 (12.0-22.0)
| |
|
Smoke
| | |
0.752
| |
0.679
|
|
Ever
|
114 (91.9)
|
85 (74.6)
| |
20.0 (16.0-26.0)
| |
|
Never
|
10 (8.1)
|
7 (70.0)
| |
16.0 (11.0-18.0)
| |
|
Pack -year
| | |
0.542
| |
0.861
|
|
≤ 40
|
60 (48.4)
|
46 (75.0)
| |
19.0 (14.0-29.0)
| |
|
> 40
|
64 (51.6)
|
46 (73.0)
| |
20.0 (13.0-29.0)
| |
|
Histology
| | |
0.828
| |
0.632
|
|
Adenocarcinoma
|
40 (32.3)
|
31 (77.5)
| |
20.0 (17.0-31.0)
| |
|
Squamous cell
|
38 (31.6)
|
28 (73.7)
| |
16.0 (12.0-25.0)
| |
|
Others
|
46 (37.1)
|
33 (71.7)
| |
24.0 (13.0-36.0)
| |
|
KPS
| | |
0.175
| |
0.067
|
|
90-100
|
38 (30.7)
|
24 (66.2)
| |
22.0 (16.0-39.0)
| |
|
80
|
67 (54.0)
|
53 (79.1)
| |
20.0 (14.0-27.0)
| |
|
< 80
|
19 (15.3)
|
15 (79.0)
| |
13.0 (8.0-29.0)
| |
|
Stage
| | |
0.057
| |
0.088
|
|
IIIa
|
52 (41.9)
|
34 (65.4)
| |
20.0 (16.0-39.0)
| |
|
IIIb
|
72 (58.1)
|
58 (80.6)
| |
17.0 (13.0-23.0)
| |
|
Chemotherapy
| | |
0.186
| |
0.766
|
|
Yes
|
112 (90.3)
|
85 (75.9)
| |
20.0 (16.0-26.0)
| |
|
No
|
12 (9.7)
|
7 (58.3)
| |
17.0 (11.0-44.0)
| |
|
Radiotherapy dose
| | |
0.360
| |
0.857
|
|
< 70Gy
|
59 (47.6)
|
46 (78.0)
| |
21.0 (16.0-33.0)
| |
|
≥ 70Gy
|
65 (52.4)
|
46 (70.8)
| |
17.0 (12.0-24.0)
| |
- Abbreviations: MST, median survival time.
- * Percentage of deaths in each stratum.
-
† Chi -square test for difference in the distribution of deaths.
-
‡ Log-rank test for survival time in the univariate analysis.
